First patient dosed in rectal cancer BT-001 trial
Phase 1 study targets hard-to-treat patients
Read More
Author: John Pinching
Nxera signs $1.47bn AbbVie licensing deal
Agreement covers IBD drug candidate
Read More
Myeloma fund launches with £15m initial backing
Philanthropy initiative targets treatment innovation
Read More
Teva expands biosimilars alliance with Samsung Bioepis
Agreement covers two FDA-approved immunology treatments
Read More
Santersus advances nucleoCapture into pivotal sepsis study
Axcellant appointed global CRO for multinational trial
Read More
